Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Blueprint Medicines Corp Market Cap
The Blueprint Medicines Corp (BPMC) share price is expected to increase by 6.53% over the next year. This is based on calculating the average 12-month share price estimate provided by 13 stock analysts who have covered BPMC. Price targets range from $50.00 at the low end to $114.00 at the high end. The current analyst consensus for BPMC is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 13 Wall Street analysts have assigned BPMC 10 buy ratings, 1 hold ratings, and 2 sell ratings. This means that analysts expect Blueprint Medicines Corp to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on BPMC. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| reni benjamin JMP Securities | Buy | $114.0 | reiterated | Feb 16, 2024 |
| andrew berens Leerink Partners | Sell | $50.0 | maintained | Feb 16, 2024 |
| derek archila Wells Fargo | Buy | $107.0 | maintained | Feb 15, 2024 |
| matthew biegler Oppenheimer | Buy | $99.0 | maintained | Feb 15, 2024 |
| eun yang Jefferies | Buy | $94.0 | maintained | Jan 22, 2024 |
| christopher raymond Piper Sandler | Hold | $78.0 | rated | Jan 19, 2024 |
| david nierengarten Wedbush | Buy | $97.0 | maintained | Jan 9, 2024 |
| bradley canino Stifel Nicolaus | Buy | $97.0 | maintained | Jan 9, 2024 |
| colleen m. kusy Robert W. Baird | Buy | $112.0 | reiterated | Jan 9, 2024 |
| salveen richter Goldman Sachs | Buy | $114.0 | maintained | Jan 9, 2024 |
| michael schmidt Guggenheim | Buy | $90.0 | maintained | Jan 2, 2024 |
| david lebovitz Citi | Sell | $54.0 | maintained | Dec 11, 2023 |
| andrew fein H.C. Wainwright | Buy | $85.0 | reiterated | Dec 11, 2023 |
| ami fadia Needham | Buy | $74.0 | maintained | Oct 27, 2023 |
| michael ulz Morgan Stanley | Hold | $63.0 | maintained | Oct 27, 2023 |
| peter lawson Barclays | Hold | $58.0 | maintained | Oct 27, 2023 |
| joel beatty Robert W. Baird | Buy | $96.0 | maintained | Oct 26, 2023 |
| marc frahm TD Cowen | Buy | None | reiterated | Oct 26, 2023 |
| gaurav goparaju Berenberg Bank | Buy | $90.0 | initiatedcoverage | Oct 25, 2023 |
| liana moussatos Wedbush | Buy | $75.0 | reiterated | May 23, 2023 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
When did it IPO
2015
Staff Count
655
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Ms. Kathryn Haviland
Market Cap
$5.34B
In 2023, BPMC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BPMC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
LANC-USD
$193.94
$21.58
CNXC-USD
$81.94
$53.37
FCFS-USD
$117.29
NUVL-USD
$86.21
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
